Clinical stage biopharmaceutical company Pulmatrix Inc (NASDAQ: PULM) announced on Monday that Rick Batycky PhD has been appointed to its board of directors.

With more than two decades of experience with biotech start-ups from founding to acquisition across an array of platforms and disease states with significant expertise in inhaled drug development, Dr Batycky currently serves as CEO at Nocion Therapeutics.

Dr Batycky was the chief scientific officer and a founder of Civitas Therapeutics, which was acquired by Acorda. Whilst at Acorda, Dr Batycky was chief technology officer .

Previously, Dr Batycky was chief scientific officer and senior VP of R&D at Pulmatrix and held prior positions at Alkermes and Advanced Inhalation Research.

Pulmatrix is developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE technology. Its proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis (ABPA) and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease (COPD).